Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

533966 LDH-A Inhibitor III, NHI-1 - CAS 1269802-68-7 - Calbiochem

A cell-permeable, both NADH and pyruvate-competitive isoform A-selective LDH inhibitor. Exhibits enhanced anticancer activity under hypoxic conditions.

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: 1-Hydroxy-6-phenyl-4-trifluoromethyl-1H-indole-2-carboxylic acid, Lactate Dehydrogenase A Inhibitor III, LDH-M Inhibitor III

Primary Target: LDH-A/LDH-1
533966
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
1269802-68-7C₁₆H₁₀F₃NO₃

Products

Catalogue NumberPackaging Qty/Pack
5339660001 Glass bottle 10 mg
Description
OverviewA cell-permeable, non-cytotoxic N-hydroxyindole (NHI) carboxylate that acts as a potent, reversible, and isoform selective inhibitor of lactic dehydrogenase (LDH) A/LDH-1. Inhibition appears to be competitive with respect to both pyruvate (Ki = 4.7 µM) and NADH (cofactor; Ki = 8.9 µM). Acts by occupying the whole substrate pocket and part of the cofactor pocket of LDH-A. Blocks the growth of various cancer cell lines by causing an arrest at G1 phase and inducing apoptosis (IC50 = 10.8, 10.6, 11.4, and 31.5 µM for A2780/cOHP, MSTO-211H, NIH-H28, and H630 cells, respectively). Exhibits enhanced anticancer activity under hypoxic conditions (GI50 = 0.90 µM/hypoxia vs. 16.3 µM/normoxia in LPC006 cultures) and strongly synergizes with gemcitabine (Cat. No. 504594).

Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
Catalogue Number533966
Brand Family Calbiochem®
Synonyms1-Hydroxy-6-phenyl-4-trifluoromethyl-1H-indole-2-carboxylic acid, Lactate Dehydrogenase A Inhibitor III, LDH-M Inhibitor III
References
ReferencesMaftouh, M., et al. 2014. Br. J. Cancer. 110, 172.
Granchi, C., et al. 2011. J. Med. Chem. 54, 1599.
Product Information
CAS number1269802-68-7
FormOff-white solid
Hill FormulaC₁₆H₁₀F₃NO₃
Chemical formulaC₁₆H₁₀F₃NO₃
ReversibleY
Quality LevelMQ100
Applications
Biological Information
Primary TargetLDH-A/LDH-1
Primary Target IC<sub>50</sub>10.8, 10.6, 11.4, and 31.5 µ
Purity≥98% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
5339660001 04055977281651

Documentation

LDH-A Inhibitor III, NHI-1 - CAS 1269802-68-7 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

References

Reference overview
Maftouh, M., et al. 2014. Br. J. Cancer. 110, 172.
Granchi, C., et al. 2011. J. Med. Chem. 54, 1599.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision26-June-2017 JSW
Synonyms1-Hydroxy-6-phenyl-4-trifluoromethyl-1H-indole-2-carboxylic acid, Lactate Dehydrogenase A Inhibitor III, LDH-M Inhibitor III
DescriptionA cell-permeable, noncytotoxic NHI (N-hydroxyindole) carboxylate that acts as an isoform A-selective LDH inhibitor (87% inhibition of hLDH-A4 vs 11% inhibition of hLDH-B4 at 125 µM; [NADH] = 25 µM & [pyruvate] = 2 mM) in a competitive manner with respect to both NADH (Ki = 8.9 µM; [pyruvate] = 2 mM) and pyruvate (Ki = 4.7 µM; [NADH] = 200 µM). Shown to effectively inhibit de novo D-[1,6-13C2] glucose-derived lactate production in HeLa cultures (80% and <5% of control Lac/Glu ratio in 12 h, respectively, with 400 and 500 µM inhibitor) and exhibit enhanced anticancer activity under hypoxic conditions (GI50 by SRB assays = 0.90 µM/hypoxia vs. 16.3 µM/normoxia in LPC006 cultures), while diplaying little antiproliferation activity toward non-tumorigenic hTERT-HPNE (ductal pancreatic) and Hs27 (skin fibroblast) even at concentrations as high as 100 µM;.
FormOff-white solid
Intert gas (Yes/No) Packaged under inert gas
CAS number1269802-68-7
Chemical formulaC₁₆H₁₀F₃NO₃
Purity≥98% by HPLC
SolubilityDMSO (100 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesMaftouh, M., et al. 2014. Br. J. Cancer. 110, 172.
Granchi, C., et al. 2011. J. Med. Chem. 54, 1599.